150 CF epithelial cells are primed for apoptosis as a result of increased Fas  by Weldon, S. et al.
Posters 6. Immunology/Inﬂammation S95
150 CF epithelial cells are primed for apoptosis as a result of
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Apoptosis is a physiological process essential for homeostasis of epithelial organ-
isation and function. CF lung disease is characterised by chronic infection and
inﬂammation and previous work suggests that apoptosis is dysfunctional in the CF
airways with conﬂicting results. In addition, controversy exists regarding how CFTR
misfolding contributes to apoptosis. In this study, we evaluated the relationship
between CFTR mutation and apoptosis in DF508-CFTR CF airway epithelial cells.
Basal activity of the executioner caspase, caspase-3, was signiﬁcantly increased in
CF tracheal and bronchial epithelial cell lines and primary bronchial epithelial cells
compared to non-CF controls. In addition, activity of the upstream initiator caspase,
caspase-8, was signiﬁcantly increased in CF epithelial cells compared to controls,
suggesting involvement of extrinsic apoptosis signalling, which is mediated by the
activation of death receptors, such as Fas (CD95). Increased levels of Fas were
observed in CF epithelial cells, and neutralization of Fas signiﬁcantly inhibited
caspase-3 activity in CF epithelial cells compared to untreated cells. Furthermore,
activation of Fas signiﬁcantly increased caspase-3 activity and apoptosis in CF
epithelial cells compared to control cells. Overall, these results suggest that CF
airway epithelial cells are more sensitive to apoptosis via increased levels of Fas
and subsequent activation of the Fas death receptor pathway.
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Objectives: The major cause of morbidity and mortality in Cystic Fibrosis is
gradual deterioration of pulmonary function. This has been attributed to an excessive
inﬂammatory response to chronic infection. The release of Interleukin-8 (IL-8),
from bronchial epithelial cells in particular, and the subsequent inﬂux of neutrophils
into the lungs play a large part in this process. Lowering IL-8 production, by mod-
ulating microRNAs (miRNAs), could have therapeutic beneﬁt. miRNAs are non-
coding RNAs that regulate gene transcription by degrading or preventing translation
of mRNA. Here we investigate miRNAs that regulate IL-8 gene expression.
Methods and Results: A search for miRNAs that target IL-8 was performed in
silico (TargetScan, microRNA, PITA and Microcosm Targets) and a shortlist of
possible miRNA candidates was created (n = 15). In parallel IL-8 mRNA-miRNA
complexes were isolated from human 16HBE140− bronchial epithelial cells using
custom designed biotinylated DNA oligonucleotides complementary to exposed
sequences in the IL-8 mRNA. IL-8 mRNA, but not other transcripts, was isolated
with its cognate miRNAs bound.
Conclusions: Proﬁling and validation of these IL-8 targeting miRNAs will identify
miRNAs that regulate IL-8 and represent new therapeutic targets for CF.
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Objectives: The levels of the circulating estrogen 17b-estradiol (E2) have been
viewed as an inﬂuencing factor on the progression of many lung diseases including
the gender dichotomy that exists in Cystic Fibrosis (CF). We hypothesize that E2
modulates the inﬂammatory response of circulating innate immune cells through
microRNA (miR) based modulation of Secretory Leucoprotease Inhibitor (SLPI),
a multifunctional antiprotease.
Methods: Monocytic cells [THP-1s, U937s and peripheral blood monocytes
(PBMCs)] were treated with 10 nM E2 or ethanol vehicle control for various times
up to 48 hours. miRs that were differentially expressed in THP-1s were identiﬁed
using Taqman Low Density Array. U937 cells were transfected with premiRs (miR
mimics) or antimiRs for 48 hours. SLPI mRNA and protein levels were quantiﬁed
by q-RTPCR and ELISA, respectively.
Conclusions: SLPI expression is downregulated in response to E2 in monocytic
cells (THP-1, U937 and male PBMCs). Of the 768 miRNAs proﬁled two of those
miRNAs that were upregulated by E2; miR19a and miR19b; are predicted by in
silico analysis to directly target SLPI mRNA. Transfection of U937s with premiRs
19a or 19b reduced SLPI expression at both mRNA and protein levels. This was
abrogated using antimiRs against the same miRs. The data show that E2 decreases
expression of SLPI in monocytic cells, likely via changes in miRNA expression.
Modulation of the miRNAs involved in E2-dependent regulation of SLPI expression
offers a new therapeutic approach in the treatment of inﬂammatory lung diseases
such as CF.
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Background: Cystic Fibrosis (CF) is characterised by chronic lung inﬂammation.
In CF, glucocorticoids (GC) are a widely used therapeutic tool. However, their
efﬁciency, and the beneﬁt/risk ratio are still discussed. In plasma, 90% of GC is
bound to the chaperone protein corticosteroid-binding globulin (CBG) produced
by the liver. Recent works enlightened the fact that, more than a simple carrier
protein, CBG could also address GC speciﬁcally to the inﬂammation site, thereby
modulating the response to GC in an inﬂammatory context.
Aims: Study the expression and regulation of CBG in the inﬂammatory context of
CF.
Methods: Hepatic expression: hepatocarcinoma derived cell-lines and biopsies from
healthy donors, cirrhotic CF and non CF patients: measure of transcripts and protein
levels of CBG.
Plasmatic levels: Blood samples from healthy donors, cirrhotic non CF and CF
patients: measure of CBG.
Lung expression: Bronchial epithelial cell lines; regulation of CBG expression.
Results: We observe an increase in CBG transcript and protein in the liver of CF
patients and in the hepatic and lung cell lines under pro-inﬂammatory challenge.
We show that GC have no effects on CBG expression in hepatic cell lines, but
increases CBG transcripts in the lung cell lines. Surprisingly, we observe no CBG
up-regulation in the blood of CF patients.
Discussion: Comparative results from hepatic and lung cell lines enlighten a cell-
speciﬁc regulation of CBG. Moreover, the transcript CBG up-regulation observed
in CF patients is not correlated to CBG plasma levels. We hypothesise that such
lack of increase in plasmatic CBG could participate to chronic lung inﬂammation
in CF.
